Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells

Journal of Immunology

Volumn 156, Issue 11, 1996, Pages 4298-4308

  Gorelik, Leonid ^a   Bar Dagan, Yifat ^a   Mokyr, Margalit B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TUMOR NECROSIS FACTOR;

ADOLESCENT; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOPOTENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CYTOTOXICITY, IMMUNOLOGIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNE TOLERANCE; INTERLEUKIN-12; INTERLEUKIN-2; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PLASMACYTOMA; RECOMBINANT PROTEINS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029976589     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Carswell, E., L. Old, R. Cassel, S. Green, N. Fiore, and B. Williamson. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72:630.
2. Palladino, M. A., M. R. Shalaby, S. M. Kramer, B. L. Ferraiolo, R. A. Baughman, A. B. Deleo, D. Crase, B. Marafino, B. B. Aggarwal, I. S. Figari, D. Liggitt, and J. S. Patton. 1987. Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor specific immunity. J. Immunol. 138:4023.
3. Malik, S. T. A., and F. R. Balkwill. 1992. Antiproliferative and antitumor activity of TNF in vitro and in vivo. In Tumor Necrosis Factors: Structure, Function, and Mechanism of Action. Aggarwal, B. B., and J. Vilcek, eds. Marcel Decker, New York, p. 239.
4. Asher, A. L., J. J. Mulé, C. M. Reichert, E. Shiloni, and S. A. Rosenberg. 1987. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J. Immunol. 138:963.
5. Gorelik, L., M. Rubin, A. Prokhorova, and M. B. Mokyr. 1995. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor. J. Immunol. 154:3941.
6. Vassalli, P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411.
7. Sheehan, K. F. C., and R. D. Schreiber. 1992. The synergy and antagonism of interferon-γ and TNF. In Tumor Necrosis Factors: The Molecules and Their Emerging Rolf in Medicine. Beutler, B. ed. Raven Press, New York, p. 145.
8. + T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy. Cancer Res. 50:7641.
9. Mokyr, M. B., J. C. D. Hengst, D. Przepiorka, and S. Dray. 1979. Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization. Cancer Res. 39:3928.
10. Laude, M., K. L. Siessmann, M. B. Mokyr, and S. Dray. 1991. Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured antigen-activated tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas. Cancer Res. 51:4516.
11. Weiskirch, L., Y. Bar-Dagan, and M. B. Mokyr. 1994. Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunol. Immunother. 38:215.
12. Linsley, P. S., E. A. Clark, and J. A. Ledbetter. 1990. T cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB1. Proc. Natl. Acad. Sci. USA 87:5031.
13. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
14. Lanier, L. L., S. O'Fallon, C. Somoza, J. H. Philip, P. S. Linsley, K. Okumura, D. Ito, and M. Azuma. 1995. CD80 (B7) and CD86 (B70) provide similar co-stimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154:97.
15. Inge, E. A., J. H. Hess, S. Huang, M. Aguet, J. Rothe, H. Bluethmann, and S. H. E. Kaufmann. 1995. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon γ and tumor necrosis factor α. J. Exp. Med. 181:1615.
16. Ross, H. J., and Koeffler, H. P. 1992. Interactions between TNF and GM-CSF. In Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. Beutler, B. ed. Raven Press, New York, p. 179.
17. Bloom, E. T., and J. A. Horvath. 1994. Cellular and molecular mechanisms of IL-12-induced increase in allospecific murine cytolytic T cell activity: implications for the age-related decline in CTL. J. Immunol. 152:4242.
18. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
19. Steger G. G., R. Kaboo, J. B. deKernion, R. Figlin, and A. Belldegrum. 1995. The effect of granulocyte-macrophage colony-stimulating factor on tumor-infiltrating lymphocytes from renal cell carcinoma. Br. J. Cancer 72:101.
20. Ben-Efraim, S., R. C. Bocian, M. B. Mokyr, and S. Dray. 1983. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol. Immunother. 15:101.
21. + T cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res. 49:4597.
22. + splenic T cells from low-dose melphalan-treated MOPC-315 tumor bearers. Cancer Immunol. Immunother. 32:353.
23. Dasch, J. R., D. R. Pace, W. Waegell, D. Inenaga, and L. Ellingsworth. 1989. Monoclonal antibodies recognizing transforming growth factor-β: bioactivity neutralization and transforming growth factor β2 affinity purification. J. Immunol. 142:1536.
24. Hathcock, K. S., G. Laszlo, H. B. Dickler, J. Bradshaw, P. Linsley, and R. J. Hodes. 1993. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262:905.
25. Scharton-Kersten T., L. C. C. Afonso, M. Wysocka, G. Trinchieri, and P. Scott. 1995. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J. Immunol. 154:5320.
26. Powers, G. D., D. A. Faherty, S. E. Connaughton, D. A. Biondi, D. I. Godfrey, A. Gault, C.-Y. Chen, and N. Nabavi. 1994. Expression and functional analysis of murine B7 delineated by a novel monoclonal antibody. Cell. Immunol. 153: 298.
27. Marti, G. E., L. Magruder, W. E. Schuette, and H. R. Gralnick. 1988. Flow cytometric analysis of platelet surface antigens. Cytometry 9:448.
28. Ranges, G. E., I. S. Figari, T. Espevik, and M. A. Palladino. 1987. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J. Exp. Med. 166:991.
29. Fontana, A., K. Frei, S. Bodmer, E. Hofer, M. H. Schreier, M. A. Palladino, and R. M. Zinkernagel. 1989. Transforming growth factor-β inhibits the generation of cytotoxic T cells in virus-infected mice. J. Immunol. 141:3230.
30. Inge, T. H., S. K. Hoover, B. M. Susskind, S. K. Barrett, and H. D. Bear. 1992. Inhibition of tumor specific cytotoxic T lymphocyte responses by transforming growth factor-β1. Cancer Res. 52:1386.
31. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153: 421.
32. Sulitzeanu, D. Immunosuppressive factors in human cancer. 1991. Adv. Cancer Res. 60:247.
33. Bodmer, S., K. Strommer, K. Frei, C. Siepl, N. De Tribolet, I. Heid, and A. Fontana. 1989. Immunosuppression and transforming growth factor-β in glioblastoma: preferential production of transforming growth factor-β2. J. Immunol. 143:3222.
34. Horst, H.-A., B. W. Scheithauer, P. J. Kelly, and J. S. Kovach. 1992. Distribution of transforming growth factor-β in human astrocytomas. Hum. Pathol. 23:1284.
35. Lenschow, D. J., G. H.-T. Su, L. Zuckerman, N. Nabavi, C. L. Jellis, G. S. Gary, J. Miller, and J. A. Bluestone. 1993. Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA 90:11054.
36. Larsen, C. P., S. S. Ritchie, R. Hendrix, P. S. Linsley, K. S. Hathcock, R. J. Hodes, R. P. Lowry, and T. C. Pearson. 1994. Regulation of immunostimulatory functional costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cell. J. Immunol. 152:5208.
37. Yokota, S., T. D. Geppert, and P. E. Lipsky. 1988. Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-α. J. Immunol. 140:531.
38. Scheurich, P., B. Thoma, U. Ucer, and K. Pfizenmaier. 1988. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-α: induction of TNF receptors on human T cells and TNF-α-mediated enhancement of T cell responses. J. Immunol. 138:1786.
39. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X.-Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. Immunity 2:523.
40. Boise, L. H., P. J. Noel, and C. B. Thompson. 1995. CD28 and apoptosis. Curr. Opin. Immunol. 7:620.
41. Gorelik, L., and M. B. Mokyr. 1995. Low-dose melphalan-induced upregulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of IFN-γ in the therapeutic outcome. Cancer Immunol. Immunother. 41:363.
42. Dalton, D. K., S. Pitts-Meek, S. Keshav, I. S. Figari, A. Bradley, and T. A. Stewart. 1993. Multiple defects in immune cell function in mice with disrupted interferon-γ genes. Science 259:1739.
43. Gorelik, L., A. Prokhorova, and M. B. Mokyr. 1994. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol. Immunother. 39:117.
44. Inaba, K., M. Witmer-Pack, M. Inaba, K. S. Hathcock, H. Sakuta, M. Azuma, H. Yagita, K. Okumura, P. S. Linsley, S. Ikehara, S. Muramatsu, R. S. Hodes, and R. M. Steinman. 1994. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180:1849.
45. Colditz, I. G., and D. L. Watson. 1992. The effect of cytokines and chemotactic agonists on the migration of T lymphocytes into skin. Immunology 76:272.